Roche drug cocktail doubles chance of holding lung cancer at bay

loading...


Roche drug cocktail doubles chance of holding lung cancer at bay
ZURICH (Reuters) – Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.


Source: Health And Fitness

Reply

Pin It on Pinterest

Shares
Share This
loading...